Currently Viewing:
American Society of Hematology
Ibrutinib More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia
December 07, 2017
Patients With AL Amyloidosis From Lower Socioeconomic Status Report Lower Quality of Life
December 07, 2017
Significant Economic Burden Associated With Various AML Treatment Episodes
December 08, 2017
The Effects of Myeloproliferative Neoplasm Symptoms on Quality of Life
December 08, 2017
Using Time Spent at Home to Measure End-of-Life Care Quality
December 09, 2017
Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care
December 10, 2017
Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being
December 10, 2017
Dr Kerry Rogers: Ibrutinib's Impact on Vaccine Response
December 10, 2017
Dr Derek Raghavan Outlines Challenges to Implementing Evidence-Based Guidelines
December 10, 2017
Balancing Hospice Utilization With the Need for Transfusion in Leukemia
December 11, 2017
CTL019 More Cost Effective in Pediatric Patients With Acute Lymphoblastic Lymphoma
December 11, 2017
Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH
December 11, 2017
Dr Nina Shah on the Benefits of Outpatient HSCT When Possible
December 11, 2017
Dr Thomas LeBlanc: Patients With Blood Cancers Less Likely to Use Hospice Care
December 11, 2017
CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients
December 11, 2017
Dr Joshua Richter Discusses Patient Financial Burden of New Treatments and Cures
December 12, 2017
Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children
December 12, 2017
New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study
December 12, 2017
Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma
December 12, 2017
Diagnosing Non-Chemotherapy Drug-Induced Neutropenia
December 16, 2017
Care Utilization Patterns in Sickle Cell Disease: Managing Pain and Care Transitions in AYAs
December 18, 2017
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 18, 2017
Currently Reading
Dr Derek Raghavan: Ensuring Guidelines Are Implemented and Followed
December 22, 2017
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25, 2017

Dr Derek Raghavan: Ensuring Guidelines Are Implemented and Followed

Electronic health records can be used to measure and record how guidelines are being implemented and followed, but more government intervention is needed to regulate electronic health records and set standards, Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.


Electronic health records can be used to measure and record how guidelines are being implemented and followed, but more government intervention is needed to regulate electronic health records and set standards, Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.

Transcript

Once guidelines have been implemented, what strategy should be in place to ensure they are consistently followed?

I think the key is measuring the use of guidelines and the type and patterns of treatment. We now, with all the electronic health records available, have mechanisms to measure what actually happens. Oftentimes, that isn’t done, so it becomes very important for physician leaders, the leader of the pharmacies that supply medications—either to individual practitioners or to group practitioners—to actually work together to measure outcomes, to record outcomes, and to know exactly what is being done.

We’ve had, over the years, a bit of a tendency of what you might call laissez-faire—leaving the people alone, hoping they’ll do the best job they can. And that’s a good implicit concept, but now that we have mechanisms to measure what we’re doing, we need to do that and then to implement those measurements, to understand the results of what we’re doing.

One of the biggest challenges is that so many of the electronic health record systems are so hard to use, they add a lot of working time to the average clinician’s day. And, unfortunately, most of the electronic health records are sold without any measure of government oversight or any requirement for the records to produce what they promise. So, this is going to have to be an area where government gets more actively involved in.

Today, you can sell an electronic health record, as far I know, to anybody. Given that it can have such a big impact on the delivery of healthcare, it’s probably time, in the same way that the physicians and the pharmaceutical industry are being regulated, I think it’s time for the government to start to look at the companies that make electronic health records and set standards of what they need to produce. That, in turn, will allow a much better level of systematization of care.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up